Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.
Department of Neurology, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.
Ann Neurol. 2019 Mar;85(3):448-454. doi: 10.1002/ana.25414. Epub 2019 Jan 28.
High levels of antibodies against glutamic acid decarboxylase (GAD) are observed in patients with different neurological disorders, but cells producing these autoantibodies are largely unexplored. We detect circulating GAD-reactive B cells in peripheral blood that readily differentiate into antibody-producing cells. These cells are highly elevated in most patients with GAD-antibody-associated disorders (n = 15) compared to controls (n = 19). They mainly produce GAD65 antibodies of the IgG1 and IgG4 subclasses and are as abundant as B cells reactive for common recall antigens. Bone marrow cells represent an additional source of GAD antibodies. The identification of GAD-antibody-producing cells has implications for the selection of cell-specific biologics. ANN NEUROL 2019;85:448-454.
在患有不同神经紊乱的患者中观察到高水平的谷氨酸脱羧酶 (GAD) 抗体，但产生这些自身抗体的细胞在很大程度上仍未被探索。我们在外周血中检测到循环的 GAD 反应性 B 细胞，这些细胞很容易分化为产生抗体的细胞。与对照组（n=19）相比，大多数 GAD 抗体相关疾病患者（n=15）的这些细胞水平显著升高。它们主要产生 IgG1 和 IgG4 亚型的 GAD65 抗体，与针对常见回忆抗原的 B 细胞一样丰富。骨髓细胞是 GAD 抗体的另一个来源。GAD 抗体产生细胞的鉴定对选择细胞特异性生物制剂具有重要意义。神经病学年鉴 2019;85:448-454。
